Gregory A. Winchell
Bridge Pharma (United States)(US)
Publications by Year
Research Areas
Antifungal resistance and susceptibility, HIV/AIDS drug development and treatment, Antibiotics Pharmacokinetics and Efficacy, Pneumocystis jirovecii pneumonia detection and treatment, Pharmaceutical studies and practices
Most-Cited Works
- → Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers(2006)265 cited
- → Single- and Multiple-Dose Pharmacokinetics of Caspofungin in Healthy Men(2002)246 cited
- → Disposition of Caspofungin: Role of Distribution in Determining Pharmacokinetics in Plasma(2004)137 cited
- → Potential for Interactions between Caspofungin and Nelfinavir or Rifampin(2004)99 cited
- → A Phase I/II Study of the Protease Inhibitor Indinavir in Children With HIV Infection(1998)84 cited
- → Single‐ and Multiple‐Dose Administration of Caspofungin in Patients With Hepatic Insufficiency: Implications for Safety and Dosing Recommendations(2007)66 cited
- → Pharmacokinetic Profile and Tolerability of Indinavir-Ritonavir Combinations in Healthy Volunteers(2001)60 cited
- → Use of In Vitro Drug Metabolism Data to Evaluate Metabolic Drug‐Drug Interactions in Man: The Need for Quantitative Databases(2001)45 cited
- → Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial(2020)44 cited
- → Cyclobenzaprine Pharmacokinetics, Including the Effects of Age, Gender, and Hepatic Insufficiency(2002)37 cited